OBJECTIVES:  Orphan drugs (OD) benefit from increasingly high prices leading to increased business interest from large pharmaceutical companies. The objective of this research is to compare ODs prices in France between different therapeutic classes. METHODS: All ODs approved between January 2000 and May 2015 were identified from the official website of the European Medicines Agency. When available, OD prices were collected from the official French database Ameli. Yearly price was computed for each product. Products were sorted by therapeutic class according to ICD 10. Only first approved indication and initial price at launch were considered. RESULTS: Price was available for 68 ODs from 98 approved by the EMA. Median price for all ODs was €35,643 (minimum €1,473; maximum€912,600). Price distribution was skewed justifying the use of median price. Number of products and median cost were: endocrine metabolic disorders [20_€194,804], immune disease [5_€43,680], circulatory [5_€32,850], oncology [n=27; median=€32,099], respiratory [4_€19,152], central nervous system [4_€6,944], others [3_€7,687]. Oncology product prices appear to be the fourth on the list while being the most frequent identified products (n=27). Endocrine and metabolic disorders are by far the most expensive, followed by immune disorders, and circulatory. CONCLUSIONS:  The increase approval of oncology ODs does not seem to be primarily driven by the high price of products in this area, while this may well be the case for metabolic endocrine ODs with 20 products. Although median prices are in general high, there is a large variability within and between therapeutic areas that may not be justified by the added value or level of unmet need.